Further, in contrast to the increasing effect of IL-6R inhibition in patients with rheumatoid arthritis, the effect of tocilizumab on LDL levels in both NSTEMI and STEMI patients treated with tocilizumab were limited [47, 87]. This evidence concerns the gene IL6R and rheumatoid arthritis.